Liraglutide in obesity: a guide to its use in the EU
暂无分享,去创建一个
[1] L. Aronne,et al. Liraglutide 3.0 mg reduces severity of obstructive sleep apnea and body weight in obese individuals with moderate or severe disease: scale sleep apnoea tria , 2015 .
[2] A. Astrup,et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.
[3] L. Scott. Liraglutide: A Review of Its Use in the Management of Obesity , 2015, Drugs.
[4] A. Astrup,et al. Efficacy and safety of liraglutide 3.0 mg for weight management in overweight and obese adults: the SCALE™ Obesity and Prediabetes, a randomised, double-blind and placebo-controlled trial , 2015 .
[5] L. Seoane,et al. Drug development strategies for the treatment of obesity: how to ensure efficacy, safety, and sustainable weight loss , 2014, Drug design, development and therapy.
[6] L. Scott. Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus , 2014, Drugs.
[7] L. Aronne,et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2014, International Journal of Obesity.
[8] M. Shin. Management of Overweight and Obesity: Review of the "2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults" , 2014 .
[9] B. Sloth,et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults , 2013, International Journal of Obesity.
[10] T. Wadden,et al. Long-term effect of weight loss on obstructive sleep apnea severity in obese patients with type 2 diabetes. , 2013, Sleep.
[11] G. Bray. Why do we need drugs to treat the patient with obesity? , 2013, Obesity.
[12] T. Funahashi,et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes , 2012, Cardiovascular Diabetology.
[13] C. Kapitza,et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. , 2012, Diabetes research and clinical practice.
[14] T. Funahashi,et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes , 2011, Cardiovascular Diabetology.
[15] A. Astrup,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.
[16] S. Boyle,et al. Understanding the relationship between weight loss, emotional well-being and health-related quality of life in patients attending a specialist obesity weight management service , 2011, Journal of health psychology.
[17] L. Hegedüs,et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. , 2011, The Journal of clinical endocrinology and metabolism.
[18] A. Astrup,et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.
[19] R. Collins,et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.
[20] D. Allison,et al. Waist Circumference and Cardiometabolic Risk , 2007, Diabetes Care.
[21] N. Bansback,et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis , 2009, BMC Public Health.